Publications (22) View all
-
Article: Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared to Modafinil.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND AND PURPOSE: Pitolisant, a histamine H3 receptor inverse agonist/antagonist is currently under Phase III clinical trials for treatment of excessive daytime sleepiness namely in narcoleptic patients. Its drug abuse potential was investigated using in vivo models in rodents and monkeys and compared to those of Modafinil, a psychostimulant currently used in the same indications. EXPERIMENTAL APPROACH: Effects of Pitolisant on dopamine release in the nucleus accumbens, on spontaneous and cocaine-induced locomotion, locomotor sensitization were monitored. It was also tested in three standard drug abuse testsi.e. conditioned place preference in rats, self administration in monkeys and cocaine discrimination in mice as well as in a physical dependence model. KEY RESULTS: Pitolisant did not elicit any significant changes in dopaminergic indices in rat nucleus accumbens whereas Modafinil increased dopamine release. In rodents, Pitolisant was without any effect on locomotion and reduced the cocaine-induced hyperlocomotion. In addition, no locomotor sensitization and no conditioned hyperlocomotion were evidenced with this compound in rats whereas significant effects were elicited by Modafinil. Finally, Pitolisant was devoid of any significant effects in the three standard drug abuse tests (including self administration in monkeys) and in the physical dependence model. CONCLUSIONS AND IMPLICATIONS: No potential drug abuse liability for Pitolisant was evidenced in various in vivo rodent and primate models, whereas the same does not seem so clear in the case of Modafinil.British Journal of Pharmacology 03/2013; · 4.41 Impact Factor -
Article: Effect of aging on brain-derived neurotrophic factor, proBDNF, and their receptors in the hippocampus of Lou/C rats.
[show abstract] [hide abstract]
ABSTRACT: The interest in understanding healthy aging has prompted scientist to look for animal models presenting this feature. Lou/C rats, an inbred strain of Wistar origin, is an animal model of successful aging with a longer lifespan and preserved memory capacities than most laboratory rat strains. In an attempt to shed light on this remarkable aging feature, we investigated the hippocampal patterns (mRNA and proteins) of some protective and plasticity-related molecules, i.e., brain-derived neurotrophic factor (BDNF), its precursor proBDNF, and its receptors (i.e., TrkB.FL, TrkB.T1, TrkB.T2, and p75). Using different experimental approaches, we compared these characteristics in young and aged Lou/C versus matched Wistar rats (the most appropriate controls). Data showed that young and aged Lou/C rats had higher amounts of BDNF and proBDNF content than Wistar rats. In contrast, proBDNF content was reduced in aged Lou/C rats and increased in aged Wistar rats. With aging, Lou/C rats showed a weaker decrease in TrkB.FL receptors than Wistar rats and no changes in TrkB.T1 receptors, which, contrarily, were increased in aged Wistar rats. Overall, these observations could account for the preserved cognitive performances and memory-dependent mechanisms, such as the unaltered long-term potentiation (LTP), throughout the lifespan recently reported in the Lou/C strain. Data suggest that boosting the expression or activity of these endogenous protective systems may be a promising alternative for combating some age-related cognitive declines. Therefore, Lou/C rats represent an interesting model of healthy aging for studying plasticity-related processes that evolve from youthfulness to aging.Rejuvenation Research 01/2009; 11(6):1031-40. · 3.83 Impact Factor -
Article: Developmental plasticity of the carotid chemoafferent pathway in rats that are hypoxic during the prenatal period.
[show abstract] [hide abstract]
ABSTRACT: The chemoreflex pathway undergoes postnatal maturation, and the perinatal environment plays a critical role in shaping respiratory control system. We investigated the role of prenatal hypoxia on the maturation of the chemoreflex neural circuits regulating ventilation in rat. Effects of hypoxia (10% O2) from the 5th to the 20th day of gestation were studied on male offspring at birth and on postnatal days 3, 7, 21 and 68. Maturation of the respiratory control system was assessed by in vivo tyrosine hydroxylase (TH) activity measurement in peripheral chemoreceptors (carotid bodies, petrosal ganglia), and in brainstem catecholaminergic cell groups (A2C2c and A1C1 areas in the medulla, A5 and A6 areas in the pons). Resting ventilation and ventilatory response to hypoxia were evaluated as functional sequelae. In peripheral structures, prenatal hypoxia reduced TH activity within the first postnatal week and enhanced it later. In contrast, in central areas, prenatal hypoxia upregulated TH activity within the first postnatal week and downregulated it later. The in vivo TH activity impairment is therefore tissue specific, with an opposite effect on the peripheral and central neural circuits. A shift of the effect of prenatal hypoxia occurred between 1 and 3 weeks, indicating a postnatal temporal effect of prenatal hypoxia. An important period in the development of the chemoafferent pathway occurred between the first and the third postnatal week. Functionally, prenatal hypoxia impaired resting ventilation and ventilatory response to hypoxia. The alterations of the catecholaminergic components of the chemoafferent pathway resulting from prenatal hypoxia might contribute to impair postnatal respiratory behaviour.European Journal of Neuroscience 12/2007; 26(10):2865-72. · 3.63 Impact Factor -
Article: BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.
[show abstract] [hide abstract]
ABSTRACT: Histamine H3 receptor inverse agonists are known to enhance the activity of histaminergic neurons in brain and thereby promote vigilance and cognition. 1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride (BF2.649) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor. On the stimulation of guanosine 5'-O-(3-[35S]thio)triphosphate binding to this receptor, BF2.649 behaved as a competitive antagonist with a Ki value of 0.16 nM and as an inverse agonist with an EC50 value of 1.5 nM and an intrinsic activity approximately 50% higher than that of ciproxifan. Its in vitro potency was approximately 6 times lower at the rodent receptor. In mice, the oral bioavailability coefficient, i.e., the ratio of plasma areas under the curve after oral and i.v. administrations, respectively, was 84%. BF2.649 dose dependently enhanced tele-methylhistamine levels in mouse brain, an index of histaminergic neuron activity, with an ED50 value of 1.6 mg/kg p.o., a response that persisted after repeated administrations for 17 days. In rats, the drug enhanced dopamine and acetylcholine levels in microdialysates of the prefrontal cortex. In cats, it markedly enhanced wakefulness at the expense of sleep states and also enhanced fast cortical rhythms of the electroencephalogram, known to be associated with improved vigilance. On the two-trial object recognition test in mice, a promnesiant effect was shown regarding either scopolamine-induced or natural forgetting. These preclinical data suggest that BF2.649 is a valuable drug candidate to be developed in wakefulness or memory deficits and other cognitive disorders.Journal of Pharmacology and Experimental Therapeutics 02/2007; 320(1):365-75. · 3.83 Impact Factor -
Article: BF2. 649, a non-imidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology
Journal of Pharmacology and Experimental Therapeutics 01/2006; · 3.83 Impact Factor
